Skip to main content

GL-ONC1-015: GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588 | NCT02759588

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Associated Conditions

Ovarian Cancer

Principal Investigator

Sponsor

Genelux Corporation

Trial Type: Treatment.

The purpose of this study is to determine if GL-ONC1 oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.

This study is currently enrolling.